STOCK TITAN

Esperion Appoints Craig Thompson to Board of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management

Esperion (NASDAQ: ESPR) has appointed Craig Thompson, current CEO of Cerevance, to its Board of Directors as an independent director, expanding the board to eight members. Thompson brings over 20 years of biopharmaceutical industry leadership experience and currently serves as CEO of Cerevance, a clinical-stage biotechnology company.

Thompson's extensive experience includes leadership roles at several pharmaceutical companies, notably serving as President & CEO of Neurana Pharmaceuticals, COO at Tetraphase Pharmaceuticals, and Chief Commercial Officer at Trius Therapeutics, where he was involved in its $700+ million acquisition by Cubist Pharmaceuticals. His background also includes senior positions at Pfizer and Merck & Co., where he led significant cardiovascular product initiatives.

Esperion (NASDAQ: ESPR) ha nominato Craig Thompson, attuale CEO di Cerevance, nel proprio Consiglio di Amministrazione come direttore indipendente, portando il numero dei membri a otto. Thompson vanta oltre 20 anni di esperienza nella leadership nel settore biofarmaceutico e attualmente ricopre il ruolo di CEO presso Cerevance, una società biotecnologica in fase clinica.

L'ampia esperienza di Thompson comprende ruoli di leadership in diverse aziende farmaceutiche, tra cui Presidente e CEO di Neurana Pharmaceuticals, COO di Tetraphase Pharmaceuticals e Chief Commercial Officer di Trius Therapeutics, dove ha partecipato all'acquisizione da oltre 700 milioni di dollari da parte di Cubist Pharmaceuticals. Il suo percorso professionale include anche posizioni senior in Pfizer e Merck & Co., dove ha guidato importanti iniziative nel settore cardiovascolare.

Esperion (NASDAQ: ESPR) ha nombrado a Craig Thompson, actual CEO de Cerevance, como director independiente en su Junta Directiva, ampliando la junta a ocho miembros. Thompson aporta más de 20 años de experiencia en liderazgo en la industria biofarmacéutica y actualmente es CEO de Cerevance, una empresa biotecnológica en fase clínica.

La amplia experiencia de Thompson incluye roles de liderazgo en varias compañías farmacéuticas, destacando su labor como Presidente y CEO de Neurana Pharmaceuticals, COO en Tetraphase Pharmaceuticals y Director Comercial en Trius Therapeutics, donde participó en la adquisición por más de 700 millones de dólares por parte de Cubist Pharmaceuticals. También ha ocupado cargos senior en Pfizer y Merck & Co., liderando importantes iniciativas en productos cardiovasculares.

에스페리온(NASDAQ: ESPR)은 현재 세레반스(Cerevance) CEO인 크레이그 톰슨(Craig Thompson)을 독립 이사로 이사회에 선임하여 이사회를 8명으로 확대했습니다. 톰슨은 20년 이상의 생명공학 산업 리더십 경험을 보유하고 있으며, 현재 임상 단계 바이오테크 기업인 세레반스의 CEO를 맡고 있습니다.

톰슨의 폭넓은 경험에는 여러 제약회사에서의 리더십 역할이 포함되며, 특히 뉴라나 파마슈티컬스(Neurana Pharmaceuticals) CEO 겸 사장, 테트라페이스 파마슈티컬스(Tetraphase Pharmaceuticals) COO, 트리어스 테라퓨틱스(Trius Therapeutics) 최고 상업 책임자 역할을 수행했으며, 여기서 큐비스트 파마슈티컬스(Cubist Pharmaceuticals)에 의한 7억 달러 이상의 인수에 관여했습니다. 또한 화이자(Pfizer)와 머크(Merck & Co.)에서 심혈관 제품 관련 주요 프로젝트를 이끈 고위직 경력도 있습니다.

Esperion (NASDAQ : ESPR) a nommé Craig Thompson, actuel PDG de Cerevance, au sein de son conseil d'administration en tant qu'administrateur indépendant, portant le conseil à huit membres. Thompson apporte plus de 20 ans d'expérience en leadership dans l'industrie biopharmaceutique et est actuellement PDG de Cerevance, une entreprise biotechnologique en phase clinique.

L'expérience étendue de Thompson comprend des postes de direction dans plusieurs sociétés pharmaceutiques, notamment en tant que président et PDG de Neurana Pharmaceuticals, COO chez Tetraphase Pharmaceuticals et directeur commercial chez Trius Therapeutics, où il a participé à l'acquisition de plus de 700 millions de dollars par Cubist Pharmaceuticals. Son parcours comprend également des postes de haut niveau chez Pfizer et Merck & Co., où il a dirigé d'importantes initiatives dans le domaine des produits cardiovasculaires.

Esperion (NASDAQ: ESPR) hat Craig Thompson, den derzeitigen CEO von Cerevance, als unabhängiges Mitglied in den Vorstand berufen und damit das Board auf acht Mitglieder erweitert. Thompson bringt über 20 Jahre Führungserfahrung in der biopharmazeutischen Industrie mit und ist aktuell CEO von Cerevance, einem klinisch orientierten Biotechnologieunternehmen.

Thompsons umfangreiche Erfahrung umfasst Führungspositionen bei mehreren Pharmaunternehmen, darunter als Präsident und CEO von Neurana Pharmaceuticals, COO bei Tetraphase Pharmaceuticals und Chief Commercial Officer bei Trius Therapeutics, wo er an der über 700 Millionen Dollar schweren Übernahme durch Cubist Pharmaceuticals beteiligt war. Zudem hatte er leitende Positionen bei Pfizer und Merck & Co., wo er bedeutende Initiativen im Bereich der Herz-Kreislauf-Produkte leitete.

Positive
  • Appointment brings extensive pharmaceutical commercialization and clinical development expertise to the board
  • Thompson's cardiovascular industry experience includes leadership in major heart medications like Zocor, Vytorin, and Zetia
  • Track record of successful M&A involvement, including $700+ million Trius Therapeutics acquisition
Negative
  • None.

Brings More Than Twenty Years of Biopharmaceutical Leadership Experience

ANN ARBOR, Mich., July 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr. Thompson will serve as an independent director. With Mr. Thompson’s appointment, Esperion’s Board of Directors now comprises eight members.

“We are thrilled to welcome Craig to our Board of Directors. With more than two decades of biopharmaceutical industry leadership and a proven track record advancing innovative therapies, Craig brings a wealth of strategic insight and operational expertise that will be invaluable as we continue to expand our impact in cardiovascular and cardiometabolic drug development. His deep understanding of pharmaceutical commercialization and clinical development aligns perfectly with our mission to deliver life-saving solutions to patients worldwide. We look forward to his contributions as we enter our next phase of growth and innovation,” stated Sheldon Koenig, President and CEO of Esperion.

"I am honored to join the Board of Esperion, a company at the forefront of transforming cardiovascular disease prevention. With cardiovascular conditions remaining the leading cause of death globally, the need for innovative, proactive solutions has never been greater. I look forward to working alongside this exceptional team to help guide strategic decisions and accelerate the development of impactful, science-driven approaches that can improve and extend lives," said Mr. Thompson.

Mr. Thompson has been the Chief Executive Officer and a member of the board of directors at Cerevance, a clinical stage biotechnology company focused on neurodegenerative, psychiatric, and CNS-controlled metabolic disorders, since April 2022. Mr. Thompson is also currently a member of the board of directors of NervGen Pharma Corp, a clinical stage biotechnology company focused on developing therapies for neurotrauma and neurologic diseases. Mr. Thompson was previously President & Chief Executive Officer and a member of the board of directors of Neurana Pharmaceuticals from June 2018 to April 2022. Prior to Neurana, Mr. Thompson was President & CEO of Anthera Pharmaceuticals Inc. Prior to Neurana, Mr. Thompson’s biotechnology leadership experience included serving as Chief Operating Officer for Tetraphase Pharmaceuticals Inc. and as Chief Commercial Officer for Trius Therapeutics, Inc. where he was involved in the $700+ million acquisition of Trius Therapeutics by Cubist Pharmaceuticals, Inc., and led a partnership with Bayer Pharma AG.

Before that, Mr. Thompson served in various global and U.S. leadership roles at Pfizer Inc., including Therapeutic Group Leader of Allergy, Respiratory, Pulmonary Vascular Disease and Inflammation; and he ultimately served as Vice President of Marketing for Pfizer’s Specialty Care Business Unit.

Previous to Pfizer, Mr. Thompson served in positions of increasing responsibility in global marketing at Merck & Co., where he was in product management for Zocor®, including leading the rollout of the landmark Heart Protection Study. He also was instrumental in the pre-launch planning for Vytorin® and Zetia® as part of the European partnership between Merck and Schering-Plough.

Mr. Thompson holds a Bachelor of Commerce degree from McMaster University and an MBA from the University of Notre Dame.

About Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.

Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.

Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its results, plans for potential future product candidates, financial condition and outlook, including expected cash runway, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion’s actual results to differ significantly from those projected, including, without limitation, the net sales, profitability, and growth of Esperion’s commercial products, clinical activities and results, supply chain, commercial development and launch plans, the outcomes and anticipated benefits of legal proceedings and settlements, and the risks detailed in Esperion’s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438


FAQ

Who is Craig Thompson and what is his new role at Esperion (NASDAQ: ESPR)?

Craig Thompson, currently CEO of Cerevance, has been appointed as an independent director to Esperion's Board of Directors, expanding the board to eight members.

What experience does Craig Thompson bring to Esperion's board?

Thompson brings over 20 years of biopharmaceutical leadership experience, including roles as CEO of Cerevance and Neurana Pharmaceuticals, COO at Tetraphase, and senior positions at Pfizer and Merck.

What major transactions has Craig Thompson been involved with in his career?

Thompson was involved in the $700+ million acquisition of Trius Therapeutics by Cubist Pharmaceuticals and led a partnership with Bayer Pharma AG.

How many members are now on Esperion's Board of Directors after Thompson's appointment?

With Craig Thompson's appointment, Esperion's Board of Directors now comprises eight members.

What is Craig Thompson's educational background?

Thompson holds a Bachelor of Commerce degree from McMaster University and an MBA from the University of Notre Dame.
Esperion Therape

NASDAQ:ESPR

ESPR Rankings

ESPR Latest News

ESPR Latest SEC Filings

ESPR Stock Data

200.18M
197.10M
1%
65.72%
14.73%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
ANN ARBOR